Results for 'central nervous system'

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Apr 7th • 12 mins read

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Apr 8th • 4 mins read

Advances in basic research in oncology in 2020: Bridging basic science and clinical care
Mar 24th • 1 min read

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
Feb 11th • 3 mins read

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Feb 11th • 4 mins read

Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic
Nov 22nd • 3 mins read

Advances and Challenges in Pediatric and Childhood Cancers
Jun 27th • 2 mins read

A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measure
Aug 12th • 10 mins read

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
Sep 6th • 17 mins read

Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States
Jul 21st • 12 mins read

Clinical development success rates and social value of pediatric Phase 1 trials in oncology
Jun 21st • 28 mins read

Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis
Jun 24th • 3 mins read

Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
Nov 24th • 10 mins read

Patient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort study
Feb 17th • 7 mins read

In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018
Jan 25th • 12 mins read

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Jan 20th • 20 mins read

Value assessment of oncology drugs using a weighted criterion-based approach
Dec 20th • 15 mins read

The rise of oncology biosimilars: from process to promise
Aug 23rd • 18 mins read

Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems
Jul 7th • 25 mins read

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
Jul 28th • 20 mins read